List of Excipients in Branded Drug PHESGO

PHESGO Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

PHESGO is a fixed-dose subcutaneous combination of pertuzumab, trastuzumab, and recombinant human hyaluronidase. Its commercial differentiation comes from delivery rather than a new molecular target: the formulation converts two established intravenous biologics into a single 15 mL injection administered over approximately five minutes after loading, compared with substantially longer intravenous administration times.[1]

The excipient strategy is built around four functions: stabilizing two monoclonal antibodies at high concentration, controlling pH and oxidation, enabling subcutaneous dispersion through hyaluronidase, and maintaining acceptable injection-site tolerability. The strongest commercial opportunities are in high-quality excipient supply, analytical characterization, device and container-closure systems, biosimilar co-formulation, and follow-on subcutaneous delivery platforms.

What is PHESGO and how does its formulation work?

PHESGO contains pertuzumab, trastuzumab, and hyaluronidase in a ready-to-use subcutaneous formulation.

Parameter	PHESGO specification
Brand	PHESGO
Active ingredients	Pertuzumab, trastuzumab, recombinant human hyaluronidase
Manufacturer	Genentech, a Roche company
FDA approval	June 29, 2020
Loading dose	Pertuzumab 1,200 mg; trastuzumab 600 mg; hyaluronidase 30,000 units
Maintenance dose	Pertuzumab 600 mg; trastuzumab 600 mg; hyaluronidase 20,000 units
Administration volume	15 mL
Maintenance frequency	Every three weeks
Administration route	Subcutaneous injection in the thigh
Administration time	Approximately eight minutes for the loading dose and approximately five minutes for maintenance dosing
Main indications	HER2-positive early breast cancer and metastatic breast cancer

The product is administered with an approved HER2-directed treatment regimen and chemotherapy when required by the label.[1]

PHESGO uses recombinant human hyaluronidase PH20 to transiently degrade hyaluronan in the subcutaneous space. This increases local tissue permeability and permits administration of a large-volume biologic combination that would otherwise have limited subcutaneous dispersion.

What excipients are used in PHESGO?

The PHESGO inactive ingredients are L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 20, alpha-alpha trehalose dihydrate, and water for injection.[1]

Excipient	Primary formulation role	Commercial relevance
L-histidine	Buffering agent	Controls formulation pH and supports protein stability
L-histidine hydrochloride monohydrate	Buffer component	Establishes the histidine buffer system
L-methionine	Oxidation control	Helps limit oxidative degradation of antibody residues
Polysorbate 20	Surfactant	Reduces interfacial aggregation during manufacture, storage, and injection
Alpha-alpha trehalose dihydrate	Stabilizer and tonicity contributor	Protects antibodies against physical and chemical stress
Water for injection	Vehicle	Provides the aqueous injectable medium

The formulation pH is approximately 5.5.[1] The product does not use a conventional small-molecule preservative. Its single-dose presentation supports a preservative-free strategy and reduces preservative-related compatibility and tolerability concerns.

How does the excipient strategy support commercial differentiation?

PHESGO’s excipient system supports a concentrated, co-formulated biologic product with a large subcutaneous dose. The formulation has to protect two different antibodies and maintain hyaluronidase activity in the same container.

The main technical priorities are:

1. Protein aggregation control at high concentration.
2. Preservation of pertuzumab and trastuzumab potency.
3. Maintenance of hyaluronidase enzymatic activity.
4. Control of oxidation and deamidation.
5. Reduction of particles and visible or subvisible particulate matter.
6. Acceptable injection-site tolerability.
7. Compatibility with the syringe, needle, transfer system, and manufacturing equipment.

Trehalose provides a relatively established stabilization approach for antibody products. Histidine offers a commonly used low-pH buffering system. Methionine addresses oxidation risk, which is relevant for methionine-containing proteins and can affect potency, aggregation, or charge heterogeneity. Polysorbate 20 protects against agitation and air-liquid interface stress but introduces its own degradation risks, including hydrolysis and oxidation.

For excipient suppliers, the value is not limited to compendial identity. Pharmaceutical-grade consistency, low peroxide burden, control of subvisible particles, and lot-to-lot performance can become critical qualification criteria.

What formulation risks affect PHESGO manufacturing?

PHESGO has a more complex formulation risk profile than a single-antibody intravenous product.

Polysorbate 20 degradation

Polysorbate 20 can undergo hydrolysis and oxidation. Degradation may generate free fatty acids, particles, or reactive species that affect protein stability. Suppliers with controlled peroxide levels, defined impurity profiles, and strong stability data have a commercial advantage.

High-concentration antibody behavior

The maintenance dose contains 1,200 mg of combined antibody in a 15 mL injection. High protein concentration can increase viscosity, aggregation, opalescence, and delivery force. These factors affect both manufacturing yield and the patient experience.

Hyaluronidase compatibility

Hyaluronidase must remain active while the antibodies remain stable. Changes in pH, ionic strength, temperature, agitation, or excipient quality can affect enzyme activity. A formulation that stabilizes the antibodies but reduces hyaluronidase activity would undermine the subcutaneous delivery mechanism.

Container-closure interaction

The product must be compatible with the primary container, elastomeric components, syringe or vial system, and administration accessories. Silicone oil, tungsten residues, extractables, leachables, and particles are material risks for concentrated biologics.

Subcutaneous tolerability

A 15 mL injection imposes local volume and osmolality constraints. The formulation must balance concentration against injection-site pain, swelling, erythema, and tissue pressure. Hyaluronidase improves dispersion but does not eliminate local tolerability risk.

What commercial opportunities exist for PHESGO-related excipients?

High-purity polysorbate 20

The most direct opportunity is supply of pharmaceutical-grade polysorbate 20 with improved control of oxidation, hydrolysis, and particulate formation. Suppliers can differentiate through:

• Low peroxide and aldehyde levels.
• Defined fatty-acid composition.
• Batch-specific oxidative stability.
• Low bioburden and endotoxin control.
• Improved analytical packages for biologic comparability.
• Supply redundancy and regional manufacturing.

A supplier that is qualified into a commercial biologic formulation benefits from high switching costs. Changing surfactant grade can trigger formulation bridging, stability studies, process validation, and regulatory supplements.

Trehalose dihydrate

Trehalose is a relatively mature excipient, but commercial value remains in pharmaceutical-grade consistency and supply security. Potential differentiation includes particle-size control, low moisture variability, low endotoxin burden, and compatibility with high-concentration antibody formulations.

Trehalose suppliers can also pursue broader use in antibody-drug conjugates, vaccines, lyophilized products, and other biologics. PHESGO therefore provides a reference application for a wider excipient portfolio.

Methionine and histidine systems

Histidine and methionine are less differentiated on a chemical basis, but biologics manufacturers value reliable quality, low trace-metal contamination, and global regulatory support. Opportunities are strongest for suppliers that provide validated grades, dual-source production, and rapid change-control support.

Recombinant hyaluronidase

The highest-value component is recombinant human hyaluronidase. PHESGO relies on the enzyme to enable subcutaneous administration of a large-volume antibody combination. Hyaluronidase supply is therefore a strategic manufacturing constraint rather than a routine excipient purchase.

Halozyme has commercialized recombinant human hyaluronidase PH20 as part of its ENHANZE drug-delivery technology platform. Roche has used the technology in PHESGO under a collaboration and licensing arrangement.[2] The commercial opportunity for alternative suppliers is significant but technically difficult because enzyme source, purity, activity, immunogenicity, and regulatory comparability are tightly linked.

What patents protect PHESGO and its delivery platform?

PHESGO protection is likely distributed across several categories rather than a single product patent.

Protection category	Relevance to PHESGO
Composition and formulation patents	May cover the fixed-dose combination, excipient system, concentration, pH, or stability profile
Method-of-use patents	May cover subcutaneous administration for HER2-positive breast cancer
Delivery-platform patents	May cover recombinant hyaluronidase-enabled subcutaneous administration
Manufacturing patents	May cover preparation, filling, mixing, or stability control
Container and device rights	May cover syringes, injection systems, or administration configurations
Regulatory exclusivity	Provides biologic reference-product protection separate from patent rights

PHESGO is a biologic, so it does not have an FDA Orange Book listing. The FDA Purple Book is the relevant reference for biologic exclusivity and biosimilar information.[3] Paragraph IV certification is an abbreviated new drug application mechanism for small-molecule drugs and does not apply to PHESGO in the same manner.

The FDA approved PHESGO in 2020. Reference-product exclusivity for a biologic is generally 12 years from first licensure under the Public Health Service Act, subject to statutory details and product-specific regulatory analysis.[4] On that basis, U.S. biosimilar competition is unlikely to rely only on the expiration of a conventional composition patent and must account for the biologic regulatory pathway, patent litigation, and the delivery technology.

A precise freedom-to-operate conclusion requires claim-by-claim review of live U.S. and foreign patent families. Public regulatory documents alone do not establish the complete set of enforceable claims.

When does PHESGO lose exclusivity?

PHESGO faces three separate exclusivity questions:

1. FDA biologic reference-product exclusivity.
2. Patent expiry and enforceability.
3. Biosimilar approval and commercial launch timing.

The practical U.S. competition date could occur after the 12-year reference-product period if relevant patents, settlements, manufacturing barriers, or delivery-platform rights delay entry. It could also be earlier in markets with different regulatory and patent rules.

Milestone	Timing or status
FDA approval	June 2020
Standard U.S. biologic reference-product period	Generally 12 years from first licensure
Orange Book status	Not listed as a small-molecule drug
Purple Book status	Relevant biologic reference-product source
Paragraph IV risk	Not applicable in the conventional ANDA sense
Biosimilar pathway	FDA 351(k) pathway
Likely competitive constraints	Patents, analytical comparability, hyaluronidase access, manufacturing scale, and clinical positioning

Which companies are challenging PHESGO?

The competitive field includes three groups:

Trastuzumab and pertuzumab biosimilar developers

Companies developing biosimilars to trastuzumab or pertuzumab could seek to reproduce the clinical value of the two antibodies, but a direct PHESGO-like product requires more than separate biosimilars. It requires a stable fixed-dose combination and a subcutaneous delivery system.

Subcutaneous delivery competitors

Halozyme’s technology is a major platform competitor and potential licensing gatekeeper for products using recombinant hyaluronidase PH20. Other developers may pursue alternative hyaluronidase enzymes, different delivery devices, or lower-volume high-concentration formulations.

Intravenous and other fixed-dose regimens

Intravenous Perjeta and Herceptin, trastuzumab biosimilars, pertuzumab biosimilar programs, and oncology regimens that reduce administration burden compete with PHESGO on price, procurement flexibility, and clinical familiarity.

What is the FDA regulatory status of PHESGO?

PHESGO is FDA-approved for HER2-positive breast cancer settings described in its prescribing information.[1] Its regulatory value comes from the combination of two validated biologics with a new route and administration format.

The regulatory burden for a follow-on product includes:

• Demonstrating analytical similarity for pertuzumab and trastuzumab.
• Establishing comparable hyaluronidase activity.
• Addressing combination-product manufacturing controls.
• Demonstrating comparable pharmacokinetics and immunogenicity.
• Supporting the proposed route of administration.
• Controlling particles, aggregates, charge variants, and degradation products.
• Establishing device and container compatibility.

A biosimilar applicant seeking substitution or interchangeability may face additional requirements depending on the product design and FDA pathway.

How strong is the PHESGO patent and excipient estate?

PHESGO has a technically defensible product profile because the commercial product combines:

• Two high-value monoclonal antibodies.
• A high-volume subcutaneous injection.
• Recombinant hyaluronidase.
• A fixed-dose formulation.
• Specialized manufacturing and analytical controls.
• A branded administration workflow.

The strongest barriers are likely to be delivery-platform rights, formulation know-how, hyaluronidase supply, and manufacturing comparability. Basic excipient patents are less likely to be the principal barrier because histidine, methionine, trehalose, and polysorbate 20 are established excipients. Their commercial importance lies in qualified grade, performance, and regulatory history.

What generic and biosimilar launch scenarios exist for PHESGO?

Scenario 1: Separate intravenous biosimilars

Competitors launch trastuzumab and pertuzumab biosimilars as intravenous products. This creates price pressure but does not fully replicate PHESGO’s administration advantage.

Scenario 2: Subcutaneous trastuzumab competition

Subcutaneous trastuzumab products compete for patients and infusion-center capacity. The impact is strongest where pertuzumab is not required or where payers prioritize lower acquisition cost.

Scenario 3: Direct PHESGO-like biosimilar

A competitor develops a fixed-dose pertuzumab/trastuzumab product with subcutaneous delivery. This has the greatest potential to challenge PHESGO but also faces the highest formulation, regulatory, patent, and supply barriers.

Scenario 4: Non-hyaluronidase delivery

A competitor uses a different delivery approach, such as a lower-volume formulation, alternative permeation technology, or device-enabled injection. This could avoid some platform restrictions but would require substantial development and clinical validation.

What licensing opportunities are linked to PHESGO?

The core licensing opportunity is the use of recombinant human hyaluronidase for subcutaneous delivery of large biologic doses. A platform license can provide access to enzyme technology, technical development support, and a regulatory package. The economic value depends on product sales, territorial rights, milestones, royalties, manufacturing obligations, and exclusivity.

Other licensing opportunities include:

• Co-formulation rights for dual-antibody products.
• Regional rights for subcutaneous oncology products.
• Contract manufacturing of high-concentration biologics.
• Excipient supply agreements with change-control protection.
• Device partnerships for large-volume subcutaneous administration.
• Analytical platforms for polysorbate degradation and protein aggregation.

What geographic opportunities exist for PHESGO-related suppliers?

The United States and Europe have the highest commercial value because of large oncology markets and established biologic reimbursement systems. Japan and other developed Asian markets offer opportunities for localized supply and regulatory support. Emerging markets may favor lower-cost biosimilars, but cold-chain capability, oncology infrastructure, and reimbursement remain limiting factors.

Excipient and hyaluronidase suppliers should prioritize dual-region manufacturing, validated shipping conditions, local regulatory documentation, and continuity-of-supply commitments. A single-site supply model creates a material risk for a commercial biologic with a specialized enzyme component.

Key Takeaways

• PHESGO combines pertuzumab, trastuzumab, and recombinant human hyaluronidase in a 15 mL subcutaneous formulation.
• Its excipient system uses histidine buffer, methionine, polysorbate 20, trehalose dihydrate, and water for injection.
• The highest-value technical risks involve polysorbate degradation, high-concentration protein stability, hyaluronidase activity, particles, and injection-site tolerability.
• Commercial opportunities are strongest in recombinant hyaluronidase, high-purity polysorbate 20, trehalose quality systems, container-closure components, and analytical services.
• PHESGO is a biologic and is not listed in the FDA Orange Book. The Purple Book and the 351(k) biosimilar pathway are more relevant.
• Direct competition must overcome formulation, delivery, patent, regulatory, and manufacturing barriers rather than simply reproduce the two antibody sequences.
• The principal licensing opportunity is access to hyaluronidase-enabled subcutaneous delivery technology.

FAQs

Is polysorbate 20 the most important PHESGO excipient?

It is one of the most important quality-sensitive excipients because oxidation and hydrolysis can affect particles and antibody stability. Recombinant hyaluronidase is more strategically important to the delivery concept.

Can PHESGO be copied by combining trastuzumab and pertuzumab biosimilars?

Separate biosimilars do not automatically create a PHESGO-equivalent product. A direct substitute would require a comparable fixed-dose formulation, subcutaneous delivery system, hyaluronidase strategy, manufacturing process, and regulatory package.

Does PHESGO have an Orange Book patent listing?

No. PHESGO is a biologic, so the FDA Purple Book, biologic exclusivity rules, patent records, and biosimilar litigation are the relevant sources.

Why is trehalose used in PHESGO?

Trehalose helps stabilize the monoclonal antibodies and contributes to formulation tonicity. Its value depends on pharmaceutical-grade purity, moisture control, and consistent performance.

What is the largest commercial barrier to a PHESGO competitor?

The combined barrier is greater than any single excipient. Hyaluronidase access, high-concentration co-formulation, analytical comparability, subcutaneous tolerability, device compatibility, patent rights, and manufacturing scale all affect launch feasibility.

References

1. U.S. Food and Drug Administration. (2024). PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) prescribing information. Genentech, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. Halozyme Therapeutics, Inc. (2024). Annual report and ENHANZE drug-delivery technology disclosures. https://ir.halozyme.com/financial-information/annual-reports

3. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov/

4. U.S. Congress. (2010). Patient Protection and Affordable Care Act, Public Health Service Act §351(k), 42 U.S.C. §262. https://www.congress.gov/111/plaws/publ148/PLAW-111publ148.pdf